MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Regeneron Pharmaceuticals Inc

Fechado

SetorSaúde

625.29 1.37

Visão Geral

Variação de preço das ações

24h

Atual

Mín

610.05

Máximo

627.04

Indicadores-chave

By Trading Economics

Rendimento

-423M

918M

Vendas

69M

3.8B

P/E

Médio do Setor

16.529

63.778

EPS

12.07

Rendimento de Dividendos

0.56

Margem de lucro

24.219

Funcionários

15,106

EBITDA

-534M

1.1B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+51.62% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.56%

2.39%

Próximos Ganhos

29 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-5B

70B

Abertura anterior

623.92

Fecho anterior

625.29

Sentimento de Notícias

By Acuity

52%

48%

321 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Regeneron Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de fev. de 2025, 12:13 UTC

Ganhos

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

8 de jul. de 2024, 12:00 UTC

Ganhos

Regeneron Expects Earnings Hit After $24 Million R&D Charge

28 de fev. de 2025, 12:00 UTC

Principais Notícias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 de fev. de 2025, 11:58 UTC

Ganhos

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 de fev. de 2025, 11:37 UTC

Ganhos

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 de fev. de 2025, 11:37 UTC

Ganhos

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 de fev. de 2025, 11:36 UTC

Ganhos

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 de fev. de 2025, 11:35 UTC

Ganhos

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 de fev. de 2025, 11:35 UTC

Ganhos

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 de fev. de 2025, 11:34 UTC

Ganhos

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 de fev. de 2025, 11:34 UTC

Ganhos

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4 de fev. de 2025, 11:32 UTC

Ganhos

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4 de fev. de 2025, 11:31 UTC

Ganhos

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31 de jan. de 2025, 08:30 UTC

Aquisições, Fusões, Aquisições de Empresas

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28 de jan. de 2025, 10:30 UTC

Principais Notícias

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31 de out. de 2024, 13:58 UTC

Ganhos

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31 de out. de 2024, 10:52 UTC

Ganhos

Regeneron Earnings Top Views For Biotech Giant -- IBD

31 de out. de 2024, 10:34 UTC

Ganhos

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31 de out. de 2024, 10:33 UTC

Ganhos

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31 de out. de 2024, 10:33 UTC

Ganhos

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31 de out. de 2024, 10:32 UTC

Ganhos

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31 de out. de 2024, 10:30 UTC

Ganhos

Regeneron Pharma 3Q Rev $3.72B >REGN

31 de out. de 2024, 10:30 UTC

Ganhos

Regeneron Pharma 3Q EPS $11.54 >REGN

31 de out. de 2024, 10:30 UTC

Ganhos

Regeneron Pharma 3Q Net $1.34B >REGN

25 de out. de 2024, 20:25 UTC

Ganhos

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1 de ago. de 2024, 11:50 UTC

Ganhos

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 de ago. de 2024, 10:37 UTC

Ganhos

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 de ago. de 2024, 10:30 UTC

Ganhos

Regeneron Pharma 2Q EPS $12.41 >REGN

1 de ago. de 2024, 10:30 UTC

Ganhos

Regeneron Pharma 2Q Net $1.43B >REGN

1 de ago. de 2024, 10:30 UTC

Ganhos

Regeneron Pharma 2Q Rev $3.55B >REGN

Comparação entre Pares

Variação de preço

Regeneron Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

51.62% parte superior

Previsão para 12 meses

Média 948.55 USD  51.62%

Máximo 1,182 USD

Mínimo 575 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Regeneron Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

16

Comprar

3

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 662.33Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

321 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.